Third Quarter 2026 Operating & Financial Results Conference Call - MIMEDX GROUP INC

Financial Performance:

• Net sales for Q3 2026 were $62 million, down 45% year-over-year (YoY) due to significant headwinds in the wound care segment.
• Surgical revenue reached $40 million, up 9% YoY; underlying surgical volume grew in the mid-teens, though reported growth was dampened by $1 million in prior-year one-time B2B sales and higher rebate adjustments.
• Wound care revenue was $22 million, down 71% YoY, impacted by 2026 Medicare reimbursement changes and volume disruptions.
• Gross profit was $50 million with an 80% gross margin, representing an 11 percentage point sequential improvement driven by cost reductions and manufacturing efficiency.
• Adjusted EBITDA turned positive at $2 million, a $10 million sequential improvement from Q2; GAAP net loss was $9 million ($0.06/share) vs. a $17 million GAAP net income in the prior year.
• Liquidity ended the quarter with $121 million in net cash; the company is debt-free after repaying the final $17 million on its term loan.
• Sales and marketing expenses were $40 million (64% of net sales), reduced from $54 million YoY due to cost-cutting initiatives.

Guidance and Future Outlook:

• Updated full-year 2026 standalone net sales guidance to $250–$260 million.
• Q4 standalone guidance forecasts high-single-digit YoY surgical growth and mid-single-digit sequential wound care growth.
• Q4 gross margin expected to remain stable at approximately 80%; sales and marketing expenses projected at 58–60% of net sales.
• Following the proposed Sonara acquisition, the combined entity expects run-rate revenue close to $400 million in the first full year.
• The combined company anticipates $20 million+ in annualized cost synergies and an adjusted EBITDA margin exceeding 20% in the first year of integration.
• Net leverage is expected to fall below 3x by the end of the first full year post-closing.

Business Segments and Product Lines:

• Surgical: Broad-based growth across the portfolio; flagship placental products (AmnioFix, AmnioEffect) and particulates performed well; new G4 Derm Plus product showing traction.
• Wound Care: Market transitioning; wound care center volume grew >20% YoY and 7% sequentially, offsetting declines in other outpatient sites; early traction noted with PRP offerings.
• Product Pipeline: Submitted two 510K applications for new surgical products; target for at least one clearance by year-end, including a placental-derived product.
• Legal/IP: Secured a favorable court ruling vacating the FDA's classification of Axiofil as a biological product rather than a medical device; reached a $25 million patent infringement settlement; two other active infringement cases showing favorable pre-conditions.

Market and Competitive Landscape:

• Surgical franchise benefits from a shift toward regenerative medicine, with physician demand expanding across procedures.
• Wound care market is undergoing a "reset" phase due to 2026 Medicare reimbursement changes, causing pricing pressure and lower overall volume.
• Positive trend observed in patient migration to wound care centers, a segment where the company holds a strong competitive position.
• Management anticipates the market will stabilize once the CMS reimbursement framework settles, likely reflected in the November final fee schedule publication.

Risks and Challenges:

• Regulatory Delay: The FTC issued a second request for information regarding the Sonara acquisition, extending the Hart-Scott-Rodino waiting period; a modest "ticking fee" on the $300M credit facility has begun accruing.
• Reimbursement Environment: Continued disruption and volume loss in the wound care sector due to Medicare changes.
• Litigation: Two remaining patent infringement cases are still pending, though preliminary rulings have been favorable.
• Market Volatility: Difficulty in precisely predicting the timing of the wound care market's stabilization and the resulting price/volume baseline.

Management Commentary and Tone:

• Tone was optimistic and confident, emphasizing a successful strategic pivot toward surgical growth despite significant headwinds in wound care.
• Management highlighted the company's resilience, noting a return to positive adjusted EBITDA and cash flow in Q3 after right-sizing the cost structure.
• CEO expressed strong conviction in the Sonara acquisition's strategic fit, accretive nature, and ability to accelerate the surgical business mix.
• Emphasis was placed on the company's robust IP portfolio and clinical evidence generation as long-term competitive moats.

Analyst Questions and Answers:

• Rebates: Management clarified that Q3 saw elevated rebates due to short-term promotional activities and catch-up on account targets; noted Q4 should see less volatility though some rebates remain.
• Sonara Timeline: No specific timeline provided for FTC clearance; management described interactions as "positive" and remains committed to the deal, viewing the delay as a matter of process rather than substance.
• Margin Durability: Management expects the 80% gross margin to be durable into Q4 and potentially 2027, dependent on product mix and continued operational efficiency.
• Clinical Strategy: Confirmed continued investment in randomized controlled trials for wound care products despite lower R&D spend, viewing evidence generation as critical for long-term reimbursement stability.
• 2027 Outlook: Management indicated they do not expect significant changes to the 2027 Medicare fee schedule and view the current 2026 environment as indicative of the near-term baseline.

Other Key Points:

• The acquisition financing includes a committed $300 million first-lien senior secured term loan from Hafen Capital.
• The Axiofil court ruling is expected to resolve market concerns regarding its regulatory classification, which has been under scrutiny since 2022.
• The company has successfully right-sized its cost base, reducing compensation, travel, and meeting expenses to drive profitability.
• The strategic goal is to shift the revenue mix to approximately 75% surgical and 25% wound care post-merger.